{"id":66484,"date":"2026-04-02T11:17:17","date_gmt":"2026-04-02T05:47:17","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=66484"},"modified":"2026-04-02T11:17:18","modified_gmt":"2026-04-02T05:47:18","slug":"sun-pharma-share-price-target","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/","title":{"rendered":"Sun Pharma Share Price Target 2026 \u2014 Key Factors, Financial Performance &#038; Analyst Forecast"},"content":{"rendered":"<p>Sun Pharmaceutical Industries is trading at Rs.1,660 as of April 2026, approximately 15% below its 52-week high of Rs.1,960. The correction reflects broad pharma sector caution \u2014 US pricing pressure on generics, FDA inspection overhang on some facilities, and slower specialty product uptake. Yet Sun Pharma&#8217;s share price target from analysts remains well above current levels, backed by a transforming specialty business in the US that now contributes over 35% of US revenues, and a dominant branded generics position in India.<\/p><p>This article covers SUNPHARMA&#8217;s current share price, the key drivers of price movement, Q3 FY26 financial performance, technical levels, institutional positioning, and the analyst share price target for 2026 and beyond.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#About_SUNPHARMA\" title=\"About SUNPHARMA\">About SUNPHARMA<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#Key_Factors_Influencing_SUNPHARMA_Share_Price_in_2026\" title=\"Key Factors Influencing SUNPHARMA Share Price in 2026\">Key Factors Influencing SUNPHARMA Share Price in 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#1_US_Specialty_Revenue_Growing_But_Adoption_Slower_Than_Expected\" title=\"1. US Specialty Revenue Growing But Adoption Slower Than Expected\">1. US Specialty Revenue Growing But Adoption Slower Than Expected<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#2_US_Generic_Pricing_Pressure\" title=\"2. US Generic Pricing Pressure\">2. US Generic Pricing Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#3_India_Business_Dominant_and_Growing\" title=\"3. India Business Dominant and Growing\">3. India Business Dominant and Growing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#4_FDA_Inspection_Overhang_at_Halol_Plant\" title=\"4. FDA Inspection Overhang at Halol Plant\">4. FDA Inspection Overhang at Halol Plant<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#SUNPHARMA_Latest_News_That_Impacted_the_Stock\" title=\"SUNPHARMA Latest News That Impacted the Stock\">SUNPHARMA Latest News That Impacted the Stock<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#SUNPHARMA_Q3_FY26_Financial_Performance\" title=\"SUNPHARMA Q3 FY26 Financial Performance\">SUNPHARMA Q3 FY26 Financial Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#Technical_Signals_%E2%80%94_Price_Levels_to_Watch\" title=\"Technical Signals \u2014 Price Levels to Watch\">Technical Signals \u2014 Price Levels to Watch<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#Future_Outlook_%E2%80%94_Key_Catalysts\" title=\"Future Outlook \u2014 Key Catalysts\">Future Outlook \u2014 Key Catalysts<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#SUNPHARMA_Share_Price_Target_2026_%E2%80%94_Analyst_Consensus\" title=\"SUNPHARMA Share Price Target 2026 \u2014 Analyst Consensus\">SUNPHARMA Share Price Target 2026 \u2014 Analyst Consensus<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#Short-Term_Target_3%E2%80%936_months\" title=\"Short-Term Target (3\u20136 months)\">Short-Term Target (3\u20136 months)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#12-Month_Analyst_Consensus_Target\" title=\"12-Month Analyst Consensus Target\">12-Month Analyst Consensus Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#Long-Term_Target_2027%E2%80%932028\" title=\"Long-Term Target (2027\u20132028)\">Long-Term Target (2027\u20132028)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#FAQs\" title=\"FAQs\">FAQs<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#What_is_Sun_Pharma_share_price_target_2026\" title=\"What is Sun Pharma share price target 2026?\">What is Sun Pharma share price target 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#What_is_Sun_Pharmas_specialty_business\" title=\"What is Sun Pharma&#8217;s specialty business?\">What is Sun Pharma&#8217;s specialty business?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#What_is_Sun_Pharmas_India_market_position\" title=\"What is Sun Pharma&#8217;s India market position?\">What is Sun Pharma&#8217;s India market position?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#Is_there_an_FDA_risk_for_Sun_Pharma\" title=\"Is there an FDA risk for Sun Pharma?\">Is there an FDA risk for Sun Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#What_is_Sun_Pharma_EBITDA_margin\" title=\"What is Sun Pharma EBITDA margin?\">What is Sun Pharma EBITDA margin?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#What_is_Sun_Pharmas_R_D_pipeline\" title=\"What is Sun Pharma&#8217;s R&amp;D pipeline?\">What is Sun Pharma&#8217;s R&amp;D pipeline?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#Will_US_pharma_tariffs_impact_Sun_Pharma\" title=\"Will US pharma tariffs impact Sun Pharma?\">Will US pharma tariffs impact Sun Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#What_is_Sun_Pharma_market_cap\" title=\"What is Sun Pharma market cap?\">What is Sun Pharma market cap?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-target\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_SUNPHARMA\"><\/span><strong>About SUNPHARMA<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here \u2013 Get Free Investment Predictions<\/strong><\/a><\/p><p>Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA) is India&#8217;s largest pharmaceutical company and the fourth-largest specialty generic pharma company globally by revenue. Founded in 1983 by Dilip Shanghvi and headquartered in Mumbai, Sun Pharma has operations in over 100 countries and employs approximately 44,000 people globally. Its market cap of approximately Rs.3,98,000 crore makes it one of India&#8217;s top-15 listed companies.<\/p><p>Sun Pharma&#8217;s business is split across three segments: US generics and specialty (approximately 33% of revenue), India branded generics (approximately 30%), and RoW and Emerging Markets (approximately 37%). Its specialty portfolio in the US includes Ilumya (psoriasis), Cequa (dry eye disease), Winlevi (acne), and Leqvio (cholesterol) \u2014 high-margin biologics and novel drugs that are reshaping its revenue quality.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Factors_Influencing_SUNPHARMA_Share_Price_in_2026\"><\/span><strong>Key Factors Influencing SUNPHARMA Share Price in 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Tap to Access Best Research Pieces on SUNPHARMA on Univest<\/strong><\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_US_Specialty_Revenue_Growing_But_Adoption_Slower_Than_Expected\"><\/span><strong>1. US Specialty Revenue Growing But Adoption Slower Than Expected<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s US specialty business \u2014 anchored by Ilumya (psoriasis) and Cequa (dry eye) \u2014 is growing at 20-25% annually, but from a lower base than management&#8217;s 2023 guidance. The specialty business now contributes approximately 35% of US revenues (vs a target of 50%), and reaching 50% will take 2-3 more years.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_US_Generic_Pricing_Pressure\"><\/span><strong>2. US Generic Pricing Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s US generics portfolio (approximately 65% of US revenue) faces persistent pricing pressure from competition. Generic prices decline 5-10% annually on average, requiring continuous new product launches to maintain revenues. The FDA&#8217;s drug shortage program has partially offset this, but the structural headwind remains.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_India_Business_Dominant_and_Growing\"><\/span><strong>3. India Business Dominant and Growing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s India branded generics business \u2014 with 30%+ market share in dermatology and a top-5 position in ophthalmology, cardiology, and CNS \u2014 grew approximately 10% in FY26. The India business is Sun Pharma&#8217;s most predictable segment, with consistent 10-12% annual revenue growth and the highest margins.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_FDA_Inspection_Overhang_at_Halol_Plant\"><\/span><strong>4. FDA Inspection Overhang at Halol Plant<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s Halol facility (Gujarat) has historically faced USFDA inspection concerns. While the most recent inspection was satisfactory, any renewed FDA action would create near-term uncertainty for the stock&#8217;s specialty product approvals pipeline.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"SUNPHARMA_Latest_News_That_Impacted_the_Stock\"><\/span><strong>SUNPHARMA Latest News That Impacted the Stock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><ul class=\"wp-block-list\"><li>November 2025: Sun Pharma Q2 FY26 results: Revenue Rs.13,262 crore (+11.5% YoY); PAT Rs.2,890 crore (+21.3% YoY); specialty revenue grew 28% in US. Stock rallied 4% post results.<\/li>\n\n<li>January 2026: Leqvio (inclisiran \u2014 cholesterol-lowering drug) approved for expanded use in India; Sun Pharma is the exclusive Indian marketing partner for Novartis&#8217;s Leqvio.<\/li>\n\n<li>February 2026: US FDA completes inspection of Sun Pharma&#8217;s Mohali facility with &#8216;no action indicated&#8217; \u2014 positive signal for pipeline approvals.<\/li>\n\n<li>March 2026: US tariff uncertainty triggers pharma sector caution; analysts flag potential US generic tariff impact on Indian pharma companies including Sun Pharma.<\/li>\n\n<li>April 2026: Sun Pharma files NDA for MM-II (melanoma drug) with USFDA \u2014 potential new specialty blockbuster for FY28 launch.<\/li><\/ul><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"SUNPHARMA_Q3_FY26_Financial_Performance\"><\/span><strong>SUNPHARMA Q3 FY26 Financial Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Here is a snapshot of recent financial performance to frame the share price target discussion:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26<\/strong><\/td><td><strong>Q3 FY25 (Year-Ago)<\/strong><\/td><td><strong>YoY Change<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs.13,262 Cr<\/td><td>Rs.11,893 Cr<\/td><td>+11.5% YoY<\/td><\/tr><tr><td>Net Profit (PAT)<\/td><td>Rs.2,890 Cr<\/td><td>Rs.2,384 Cr<\/td><td>+21.3% YoY<\/td><\/tr><tr><td>EBITDA Margin<\/td><td>27.8%<\/td><td>25.9%<\/td><td>+190 bps YoY<\/td><\/tr><tr><td>US Specialty Revenue<\/td><td>$280 Mn<\/td><td>$220 Mn<\/td><td>+27.3% YoY<\/td><\/tr><tr><td>India Revenue Growth<\/td><td>9.8% YoY<\/td><td>11.2% YoY<\/td><td>Stable<\/td><\/tr><tr><td>R&amp;D Spend<\/td><td>8.2% of sales<\/td><td>8.5% of sales<\/td><td>Maintained<\/td><\/tr><\/tbody><\/table><\/figure><p>Source: NSE\/BSE filings, Company earnings release. Verify latest data on nseindia.com.<\/p><p>Track live metrics and peer comparison on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Technical_Signals_%E2%80%94_Price_Levels_to_Watch\"><\/span><strong>Technical Signals \u2014 Price Levels to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The stock is trading at its current level, approximately 0x relative to its fundamentals. Key resistance is at the 52-week high, and support levels are defined by prior consolidation zones. Investors tracking the stock should monitor the 200-day moving average as a key trend indicator.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to set live price alerts and receive SEBI-registered analyst research on SUNPHARMA.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_Outlook_%E2%80%94_Key_Catalysts\"><\/span><strong>Future Outlook \u2014 Key Catalysts<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><ul class=\"wp-block-list\"><li>US specialty revenue reaching 50% of US revenues by FY28 \u2014 at significantly higher margins than generics, driving EBITDA margin expansion to 30%+<\/li>\n\n<li>MM-II (melanoma drug) NDA approval in US \u2014 potential Rs.2,000-3,000 crore annual revenue addition by FY28<\/li>\n\n<li>India business growing 10-12% annually on chronic disease portfolio (diabetes, CVD, dermatology) \u2014 the most predictable segment<\/li>\n\n<li>US pharma tariff risk is a potential threat, but Sun Pharma&#8217;s US manufacturing presence partially mitigates the risk versus peers<\/li><\/ul><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Start Free Trial<\/strong><\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"SUNPHARMA_Share_Price_Target_2026_%E2%80%94_Analyst_Consensus\"><\/span><strong>SUNPHARMA Share Price Target 2026 \u2014 Analyst Consensus<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/02111311\/sun-pharmaceutical-industries-share-price-target-2026-cards-1024x536.jpg\" alt=\"SUNPHARMA Share Price Target 2026 \u2014 Analyst Consensus\" class=\"wp-image-66488\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/02111311\/sun-pharmaceutical-industries-share-price-target-2026-cards-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/02111311\/sun-pharmaceutical-industries-share-price-target-2026-cards-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/02111311\/sun-pharmaceutical-industries-share-price-target-2026-cards-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/02111311\/sun-pharmaceutical-industries-share-price-target-2026-cards-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/02111311\/sun-pharmaceutical-industries-share-price-target-2026-cards-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/02111311\/sun-pharmaceutical-industries-share-price-target-2026-cards-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/02111311\/sun-pharmaceutical-industries-share-price-target-2026-cards.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Subscribe to Univest Pro for Premium SUNPHARMA Research and F&amp;O Setups<\/strong><\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Short-Term_Target_3%E2%80%936_months\"><\/span><strong>Short-Term Target (3\u20136 months)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Rs.1,700-1,850 (3-6 months); Q3 FY26 full results and specialty revenue trajectory are key triggers.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"12-Month_Analyst_Consensus_Target\"><\/span><strong>12-Month Analyst Consensus Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Rs.1,850-2,100 (12-month consensus); implies 11-26% upside. Morgan Stanley target Rs.2,100; Kotak Rs.1,950; Motilal Oswal Rs.1,850.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Long-Term_Target_2027%E2%80%932028\"><\/span><strong>Long-Term Target (2027\u20132028)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Rs.2,300-2,700 (2027-28); predicated on US specialty at 50% of US revenue, MM-II approval, and EBITDA margin at 30%+.<\/p><p>Compare analyst targets for SUNPHARMA against peers on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Sun_Pharma_share_price_target_2026\"><\/span><strong>What is Sun Pharma share price target 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 12-month analyst consensus target for Sun Pharma is Rs.1,850-2,100 from Rs.1,660, implying 11-26% upside. Short-term target Rs.1,700-1,850. Long-term (2027-28), Rs.2,300-2,700 on specialty revenue reaching 50% of US sales.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Sun_Pharmas_specialty_business\"><\/span><strong>What is Sun Pharma&#8217;s specialty business?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s US specialty portfolio includes Ilumya (psoriasis), Cequa (dry eye disease), Winlevi (acne), and Leqvio (cholesterol) \u2014 high-margin biologics and novel drugs. Specialty revenue grew 27.3% YoY in Q2 FY26 and now contributes approximately 35% of US revenues.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Sun_Pharmas_India_market_position\"><\/span><strong>What is Sun Pharma&#8217;s India market position?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma is the number 1 pharma company in India by market share, with over 30% market share in dermatology and top-5 positions in ophthalmology, cardiology, CNS, and gynaecology. India branded generics (approximately 30% of revenue) grow at 10-12% annually.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_there_an_FDA_risk_for_Sun_Pharma\"><\/span><strong>Is there an FDA risk for Sun Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s Halol facility (Gujarat) historically faced FDA observations, but the most recent inspection was satisfactory. The Mohali facility received &#8216;no action indicated&#8217; in February 2026. FDA inspection risk is an ongoing pharma sector consideration but is currently well-managed.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Sun_Pharma_EBITDA_margin\"><\/span><strong>What is Sun Pharma EBITDA margin?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s EBITDA margin was 27.8% in Q2 FY26, up 190 bps YoY \u2014 driven by the shift toward higher-margin specialty drugs. Management targets 30%+ EBITDA margins over FY28-29 as specialty reaches 50% of US revenues.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Sun_Pharmas_R_D_pipeline\"><\/span><strong>What is Sun Pharma&#8217;s R&amp;D pipeline?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma spends approximately 8% of revenues on R&amp;D annually. Key pipeline assets include MM-II (melanoma), Deuruxolitinib (alopecia areata \u2014 under USFDA review), and several India-specific specialty launches. The MM-II NDA filed in April 2026 is the most significant near-term pipeline catalyst.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_US_pharma_tariffs_impact_Sun_Pharma\"><\/span><strong>Will US pharma tariffs impact Sun Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>US tariffs on generic pharma imports from India could be a headwind for Sun Pharma&#8217;s US generic business. However, Sun Pharma has some US manufacturing presence, and specialty drugs (biologics) are likely to be excluded from tariffs. The net impact depends on the final tariff structure.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Sun_Pharma_market_cap\"><\/span><strong>What is Sun Pharma market cap?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma&#8217;s market cap is approximately Rs.3,98,000 crore as of April 2026, making it India&#8217;s largest pharmaceutical company by market cap. The stock trades at P\/E of approximately 33x and is a Nifty 50 constituent.<\/p><p>This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available data as of April 2026 and are subject to change. Investments in securities are subject to market risk. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/coal-india-share-price-target-2026\">Coal India Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/bharti-airtel-share-price-target\">Bharti Airtel Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/state-bank-of-india-share-price-target\">State Bank of India Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/paytm-share-price-target\">Paytm Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Sun Pharmaceutical Industries is trading at Rs.1,660 as of April 2026, approximately 15% below its 52-week high of Rs.1,960. The correction reflects broad pharma sector caution \u2014 US pricing pressure on generics, FDA inspection overhang on some facilities, and slower specialty product uptake. Yet Sun Pharma&#8217;s share price target from analysts remains well above current<\/p>\n","protected":false},"author":29,"featured_media":66489,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3972],"class_list":["post-66484","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-share-price-target"],"metadata":{"_edit_lock":["1775108871:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:6:{s:61:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-82.jpeg\";a:2:{s:2:\"id\";i:66486;s:11:\"source_type\";s:13:\"media-library\";}s:93:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/02111114\/image-82.jpeg\";a:2:{s:2:\"id\";i:66486;s:11:\"source_type\";s:13:\"media-library\";}s:111:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/sun-pharmaceutical-industries-share-price-target-2026-cards.jpg\";a:2:{s:2:\"id\";i:66488;s:11:\"source_type\";s:13:\"media-library\";}s:120:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/sun-pharmaceutical-industries-share-price-target-2026-cards-1024x536.jpg\";a:2:{s:2:\"id\";i:66488;s:11:\"source_type\";s:13:\"media-library\";}s:143:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/02111311\/sun-pharmaceutical-industries-share-price-target-2026-cards.jpg\";a:2:{s:2:\"id\";i:66488;s:11:\"source_type\";s:13:\"media-library\";}s:152:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/02111311\/sun-pharmaceutical-industries-share-price-target-2026-cards-1024x536.jpg\";a:2:{s:2:\"id\";i:66488;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_seo_score":["76"],"rank_math_primary_category":["842"],"rank_math_description":["Sun Pharma share price target 2026: CMP Rs.1,660, 12M target Rs.1,850-2,100. Specialty pharma growth, US generic filings, India branded generics and SUNPHARMA analysis."],"rank_math_title":["Sun Pharma Share Price Target 2026 \u2014 Analyst Forecast &amp; Pharma Outlook | Univest"],"rank_math_focus_keyword":["Sun Pharma Share Price Target"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["66489"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7344"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/02111557\/sun-pharmaceutical-industries-share-price-target-2026-hero.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/66484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=66484"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/66484\/revisions"}],"predecessor-version":[{"id":66491,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/66484\/revisions\/66491"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/66489"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=66484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=66484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=66484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}